secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2023-04-26T23:59:59+00:00
Accession:  0001104659-23-050363
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics to present updated DKN-01/Gastric Cancer data at ASCO 2023
----------------------------------------------------------------------------

- Will present long-term follow-up data from Part A of Phase 2 DisTinGuish study at ASCO June 2-6, 2023.
- Presentation scheduled for June 5, 2023, at 11:30 a.m. ET; abstract #4027, poster discussion session.
- Study combines DKN-01 (anti-DKK1) + tislelizumab + chemo in first-line advanced GEA; Part A enrolled 25 pts.
- Ongoing Part C enrolling ~160 first-line HER2- GEA pts in randomized controlled trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923050363/0001104659-23-050363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923050363/tm2313816d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-050363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer